Table of Contents
- Clinical trial overview
- Study design and what it means
- Who could participate
- What was measured in the study
- Trial status and size
Clinical trial overview
The available study of Azd5462 is a Phase 2 trial in people with chronic heart failure.[1] It was designed to evaluate the effect and dose response of Azd5462 after 24 weeks of treatment in participants with heart failure.[1]
The trial was completed and enrolled 372 participants.[1]
Study design and what it means
This study was a randomised, placebo controlled, double blind, multi-centre, dose-ranging study.[1]
Randomised means participants were assigned by chance to a study group.[1] Placebo controlled means one group received a look-alike treatment with no active study drug for comparison.[1] Double blind means neither the participants nor the study staff knew who received Azd5462 or placebo during the study.[1]
Multi-centre means the trial was done at more than one study site, which can help include a wider range of participants.[1] Dose-ranging means the study compared different doses to see how response may change with dose.[1]
Who could participate
The trial focused on stable patients with chronic heart failure.[1] Stable patients are people whose heart failure is not suddenly worsening.[1]
The source data does not list more detailed entry rules, so the main known target group is adults with chronic heart failure who were stable enough to join a study like this.[1]
What was measured in the study
The primary outcome was the change in echocardiographic measurements from baseline to Week 25.[1] Primary outcome means the main result the researchers planned to measure.[1]
Echocardiographic measurements are heart measurements taken with echocardiography, an ultrasound test that shows the heart’s structure and function.[1] Baseline means the starting point before treatment begins, and Week 25 is the study visit 25 weeks later.[1]
The brief summary says the trial was meant to evaluate the effect and dose response of Azd5462 after 24 weeks of treatment in participants with heart failure.[1]
Trial status and size
The trial status is listed as Completed.[1] A total of 372 participants were enrolled.[1]
The trial used oral Azd5462 and a matching placebo tablet supplied in the same pack as the active treatment.[1]
